孟鲁司特联合西替利嗪治疗小儿变应性鼻炎的临床疗效及细胞因子水平的影响

发布时间：2018-04-18 14:24

本文选题：西替利嗪 + 鼻炎　；参考：《中国耳鼻咽喉头颈外科》2016年02期

【摘要】：目的探讨孟鲁司特钠联合西替利嗪对小儿变应性鼻炎血清干扰素γ(interferon-gamma,IFN-γ)和白细胞介素4(interleukin-1,IL-4)水平的影响及临床疗效。方法60例患儿随机分为治疗组与对照组各30例,对照组用盐酸西替利嗪滴剂,2~6岁5 mg/次,6岁10 mg/次,1次/d,口服。治疗组在对照组基础上联合孟沷司特钠,2~5岁4 mg,6~12岁5 mg,12岁10 mg,每晚睡前口服。4周为1个疗程,并设30例为健康组。结果两组治疗前与健康组比IFN-γ明显降低,IL-4明显增高(F分别为19.25、143.81,P0.01);治疗后相反,IFN-γ均升高,IL-4均降低(F分别为6.29、117.22,P0.01);LSD组间比较显示,与对照组相比,治疗组IFN-γ与IL-4水平在治疗前两组的差异无统计学意义(P0.05),而治疗后则分别显著增高与降低,差异有统计学意义(P0.01)。临床疗效:VAS评分均比治疗前降低,但治疗组更低(P0.01);治疗后与对照组比较,差异有显著性(P0.01);两组随访1个月时与治疗结束时比较,差异无显著性(P0.05)。结论孟鲁司特钠联合西替利嗪治疗小儿变应性鼻炎有明显的临床疗效,其作用机制可能与纠正紊乱的IFN-γ与IL-4有关。
[Abstract]:Objective to investigate the effects of montelukast sodium combined with cetirizine on serum interferon-gamma interferon-gamma-IFN- 纬 (IFN- 纬) and interleukin-1 interleukin-4 (IL-4) levels in children with allergic rhinitis.Methods 60 children were randomly divided into treatment group (n = 30) and control group (n = 30). The control group was treated with cetirizine hydrochloride drops for 5 mg/ at the age of 26 years and 10 mg/ times at the age of 6 years.On the basis of the control group, the treatment group was treated with montelukast sodium 2 years old, 4 mg / 6, 12 years old, 5 mg / 12, 12 years old, 10 mg / 12, taking orally 4. 4 weeks before bedtime every night as a course of treatment, and 30 cases as healthy group.Results the levels of IL-4 in the two groups were significantly lower than those in the control group (19.25143.81g, P 0.01A, P < 0.01), and the levels of IL-4 and IL-4 were lower than those in the control group (P < 0.01), which were 6.29117.22P0.01U LSD, respectively, compared with the control group, the results showed that the level of IL-4 in the two groups was significantly lower than that in the control group, and that in the control group was significantly higher than that in the control group.The levels of IFN- 纬 and IL-4 in the treatment group were not significantly different between the two groups before treatment, but significantly increased and decreased after treatment. The difference was statistically significant (P 0.01).The VAS score of clinical efficacy was lower than that before treatment, but it was lower in the treatment group than that in the control group, and there was a significant difference between the two groups after treatment and compared with the control group. There was no significant difference between the two groups at the end of 1 month follow-up and at the end of the treatment.Conclusion Montelukast sodium combined with cetirizine is effective in the treatment of allergic rhinitis in children. The mechanism of montelukast sodium combined with cetirizine may be related to correcting the disorder of IFN- 纬 and IL-4.
【作者单位】：浙江省义乌市中心医院儿科;金华职业技术学院医学院儿科;
【分类号】：R765.21

【相似文献】